Swedish Orphan Biovitrum AB Share Price

Equities

SOBI

SE0000872095

Pharmaceuticals

Market Closed - Nasdaq Stockholm 16:29:42 22/04/2024 BST 5-day change 1st Jan Change
262.8 SEK +0.69% Intraday chart for Swedish Orphan Biovitrum AB +3.38% -1.57%

Financials

Sales 2024 * 24.13B 2.22B 180B Sales 2025 * 26.84B 2.47B 200B Capitalization 89.29B 8.21B 665B
Net income 2024 * 3.53B 324M 26.25B Net income 2025 * 4.87B 448M 36.25B EV / Sales 2024 * 4.31 x
Net Debt 2024 * 14.73B 1.35B 110B Net Debt 2025 * 9.52B 875M 70.88B EV / Sales 2025 * 3.68 x
P/E ratio 2024 *
25.5 x
P/E ratio 2025 *
18.9 x
Employees 1,772
Yield 2024 *
-
Yield 2025 *
-
Free-Float 50.87%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.69%
1 week+3.38%
Current month-1.65%
1 month-2.38%
3 months-10.25%
6 months+25.74%
Current year-1.57%
More quotes
1 week
254.20
Extreme 254.2
265.80
1 month
251.00
Extreme 251
274.00
Current year
243.20
Extreme 243.2
302.00
1 year
197.90
Extreme 197.9
302.00
3 years
127.10
Extreme 127.1
302.00
5 years
127.10
Extreme 127.1
302.00
10 years
65.25
Extreme 65.25
302.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 59 21/05/17
Director of Finance/CFO 57 19/07/18
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Director/Board Member 68 31/12/20
Chairman 70 07/05/14
Director/Board Member 55 31/12/19
More insiders
Date Price Change Volume
22/04/24 262.8 +0.69% 414,483
19/04/24 261 +0.62% 314,854
18/04/24 259.4 +1.41% 323,531
17/04/24 255.8 -1.01% 225,294
16/04/24 258.4 +1.65% 259,785

Delayed Quote Nasdaq Stockholm, April 22, 2024 at 04:29 pm

More quotes
Swedish Orphan Biovitrum publ AB is a Sweden-based pharmaceutical company. The Company develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Company’s product portfolio is divided into three business segments: the Core Products segment offers pharmaceuticals within Inflammation area, and Genetics and metabolic therapeutic area; the Partner Products segment offers about 40 pharmaceuticals within hematology, oncology and emergency medicines, and the ReFacto Manufacturing segment. The Company has subsidiaries in Sweden, Denmark, Finland, Norway, United Kingdom and France, among others. On September 9, 2013, the Company acquired the full rights to develop and commercialize Kineret (anakinra) from Amgen, the biotechnology company based in the United States.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
262.8 SEK
Average target price
314.1 SEK
Spread / Average Target
+19.52%
Consensus